Abbott Xinlay Lack Of Efficacy, CV Safety Will Be Likely Focus Of Advisory Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Meta-analysis of two failed studies of atrasentan in hormone refractory prostate cancer requires confirmation in independent studies, FDA says.
You may also be interested in...
Abbott Xinlay Not Ready For Approval Or Abandonment, Committee Says
FDA's Oncologic Drugs Advisory Committee unanimously recommends against approval of Abbott's prostate cancer therapy atrasentan.
Abbott Xinlay Not Ready For Approval Or Abandonment, Committee Says
FDA's Oncologic Drugs Advisory Committee unanimously recommends against approval of Abbott's prostate cancer therapy atrasentan.
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.